SUPPRELIN Drug Patent Profile

✉ Email this page to a colleague

When do Supprelin patents expire, and what generic alternatives are available?

Supprelin is a drug marketed by Shire and Endo Pharm and is included in two NDAs. There is one patent protecting this drug.

The generic ingredient in SUPPRELIN is histrelin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the histrelin acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Supprelin

Indicators of Generic Entry

< Available with Subscription >

Try a Trial

Summary for SUPPRELIN

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	35
Clinical Trials:	2
Patent Applications:	4,740
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for SUPPRELIN
What excipients (inactive ingredients) are in SUPPRELIN?	SUPPRELIN excipients list
DailyMed Link:	SUPPRELIN at DailyMed

Drug patent expirations by year for SUPPRELIN

Recent Clinical Trials for SUPPRELIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Southwest Oncology Group	Phase 3
National Cancer Institute (NCI)	Phase 3
University of Colorado, Denver	Phase 2

See all SUPPRELIN clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for SUPPRELIN

L02AE	Gonadotropin releasing hormone analogues
L02A	HORMONES AND RELATED AGENTS
L02	ENDOCRINE THERAPY
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for SUPPRELIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shire	SUPPRELIN	histrelin acetate	INJECTABLE;INJECTION	019836-001	Dec 24, 1991		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Endo Pharm	SUPPRELIN LA	histrelin acetate	IMPLANT;SUBCUTANEOUS	022058-001	May 3, 2007		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Shire	SUPPRELIN	histrelin acetate	INJECTABLE;INJECTION	019836-002	Dec 24, 1991		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Shire	SUPPRELIN	histrelin acetate	INJECTABLE;INJECTION	019836-003	Dec 24, 1991		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for SUPPRELIN

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Shire	SUPPRELIN	histrelin acetate	INJECTABLE;INJECTION	019836-003	Dec 24, 1991	⤷ Try a Trial	⤷ Try a Trial
Shire	SUPPRELIN	histrelin acetate	INJECTABLE;INJECTION	019836-001	Dec 24, 1991	⤷ Try a Trial	⤷ Try a Trial
Shire	SUPPRELIN	histrelin acetate	INJECTABLE;INJECTION	019836-002	Dec 24, 1991	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for SUPPRELIN

See the table below for patents covering SUPPRELIN around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Japan	S565448	ORGANIC COMPOUND	⤷ Try a Trial
Denmark	241780		⤷ Try a Trial
Japan	H0132838		⤷ Try a Trial
European Patent Office	0021620	WATER-SOLUBLE PEPTIDES AFFECTING GONADAL FUNCTION	⤷ Try a Trial
Ireland	49822	WATER-SOLUBLE PEPTIDES AFFECTING GONADAL FUNCTION	⤷ Try a Trial
Austria	2617		⤷ Try a Trial
Germany	3062118		⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Indicators of Generic Entry

Summary for SUPPRELIN

Recent Clinical Trials for SUPPRELIN

Anatomical Therapeutic Chemical (ATC) Classes for SUPPRELIN

Make Better Decisions: Try a trial or see plans & pricing